Table 1.
Relationship between ING4 deletion and clinicopathologic features
| Clinicopathologic feature |
ING4 (n = 1033) |
P | |
|---|---|---|---|
| Deletion (ratio, ≤0.8) (n = 170) | No deletion (ratio, >0.8) (n = 863) | ||
| Histologic subtype | |||
| Ductal carcinoma | 132 (77.7%) | 619 (71.7%) | .113 |
| Other | 38 (22.4%) | 244 (28.3%) | |
| Size | |||
| pT1 | 51 (30.0%) | 295 (34.8%) | .258 |
| pT2 | 96 (56.5%) | 410 (48.3%) | |
| pT3 | 8 (4.7%) | 57 (6.7%) | |
| pT4 | 15 (8.8%) | 87 (10.3%) | |
| Lymph node status | |||
| N0 | 81 (53.6%) | 395 (51.6%) | .652 |
| >N0 | 70 (46.4%) | 370 (48.4%) | |
| BRE | |||
| Grade 1 | 26 (15.3%) | 183 (21.5%) | .187 |
| Grade 2 | 78 (45.9%) | 358 (42.0%) | |
| Grade 3 | 66 (38.8%) | 311 (36.5%) | |
| ER | |||
| Positive | 126 (76.8%) | 627 (74.9%) | .603 |
| Negative | 38 (23.2%) | 210 (25.1%) | |
| PR | |||
| Positive | 60 (47.2%) | 273 (42.1%) | .281 |
| Negative | 67 (52.8%) | 376 (57.9%) | |
| HER2/neu receptor | |||
| 0 + 1 | 125 (76.2%) | 699 (85.9%) | .002 |
| 2 + 3 | 39 (23.8%) | 115 (14.1%) | |
| Age at diagnosis (y), median (minimum-maximum) | 61.5 (28–88) | 63 (27–93) | .174 |
| Tumor size (mm), median (minimum-maximum) | 24 (4–110) | 25 (0–140) | .854 |
| Survival rate | |||
| 5 y (95% CI) | 81.4% (74%–87%) | 83.0% (80%-86%) | .591* |
| 6 y (95% CI) | 80.4% (72%–86%) | 81.4% (78%-84%) | |
| 10 y (95% CI) | 72.6% (62%-81%) | 71.8% (67%-76%) | |
Abbreviation: CI, confidence interval.
*
No difference in survival time throughout the duration of follow-up.